10X Genomics (TXG) revenue breakdown
By product, Products and services revenue is the largest at 93% of fiscal 2025 revenue; License and royalty revenue grew fastest, 14272% a year over 1 years.
By region, United States is the largest at 54% of fiscal 2025 revenue; China grew fastest, 47% a year over 8 years.
Revenue by product
Fiscal years, as 10X Genomics reports them in its 10-K filings; fiscal 2025 total $643M.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Products and services revenue | — | — | — | — | — | — | — | $610M | $597M | 93% |
| License and royalty revenue | — | — | — | — | — | — | — | $321,000 | $46M | 7% |
| Single Cell | — | — | — | — | — | — | $420M | — | — | — |
| Spatial | — | — | — | — | — | — | $76M | — | — | — |
| Spatial | — | — | — | — | — | — | $59M | — | — | — |
| Single Cell | — | — | — | — | — | — | $48M | — | — | — |
| Services | — | — | — | — | — | — | $16M | — | — | — |
| Chromium | — | — | — | — | $391M | $400M | — | — | — | — |
| Consumables | $46M | $108M | $207M | $253M | — | — | — | — | — | — |
| Chromium | — | — | — | — | $64M | $59M | — | — | — | — |
| Instruments | $24M | $37M | $35M | $40M | — | — | — | — | — | — |
| Spatial | — | — | — | — | $28M | $35M | — | — | — | — |
| Spatial | — | — | — | — | $303,000 | $14M | — | — | — | — |
| Services | $426,000 | $2M | $4M | $6M | $7M | $8M | — | — | — | — |
Revenue by region
Fiscal years, as 10X Genomics reports them in its 10-K filings; fiscal 2025 total $643M.
| Regions | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | — | — | $133M | $155M | $258M | $285M | $360M | $334M | $347M | 54% |
| Europe, Middle East and Africa | $19M | $36M | $58M | $73M | $108M | $117M | $142M | $160M | $162M | 25% |
| China | $3M | $15M | $30M | $42M | $78M | $64M | $51M | $57M | $70M | 11% |
| Asia-Pacific (excluding China) | $6M | $10M | $18M | $25M | $39M | $41M | $52M | $46M | $52M | 8% |
| Americas (excluding United States) | — | — | $6M | $5M | $7M | $9M | $13M | $13M | $12M | 2% |
| North America | $44M | $85M | — | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TXG.
Open TXG in InvestinglyQuestions
Where does 10X Genomics make its money?
In fiscal 2025, by product: Products and services revenue $597M, License and royalty revenue $46M.
From 10X Genomics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.